Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/29684
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16926/19260 (88%)
Visitors : 7612367      Online Users : 129
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/29684


    Title: Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease : An 8-Year Nationwide Cohort Study in Taiwan
    Authors: Hsu, Yueh-Han
    Hung, Peir-Haur
    Muo, Chih-Hsin
    Tsai, Wen-Chen
    Hsu, Chih-Cheng
    Kao, Chia-Hung
    Contributors: 生活應用與保健系
    Keywords: population-basedcohort
    hemodialysis-patients
    antiviraltreatment
    kidney-disease
    increasedrisk
    hcvinfection
    association
    dialysis
    outcomes
    metaanalysis
    Date: 2015-11
    Issue Date: 2016-04-19 19:04:31 (UTC+8)
    Publisher: Lippincott Williams & Wilkins
    Abstract: The long-term survival of end-stage renal disease (ESRD) patients with hepatitis C virus (HCV) infection who received interferon treatment has not been extensively evaluated.The HCV cohort was the ESRD patients with de novo HCV infection from 2004 to 2011; they were classified into treated and untreated groups according to interferon therapy records. Patients aged <20 years and those with a history of hepatitis B, kidney transplantation, or cancer were excluded. The control cohort included ESRD patients without HCV infection matched 4:1 to the HCV cohort by age, sex, and year of ESRD registration. We followed up all study participants until kidney transplantation, death, or the end of 2011, whichever came first. We assessed risk of all-cause mortality by using the multivariate Cox proportional hazard model with time-dependent covariate.In the HCV cohort, 134 patients (6.01%) received interferon treatment. Compared with the uninfected control cohort, the treated group had a lower risk of death (hazard ratio 0.47, 95% confidence interval [CI] 0.22-0.99). The untreated group had a 2.62-fold higher risk (95% CI 1.24-5.55) of death compared with the treated group. For the HCV cohort without cirrhosis or hepatoma, the risk of death in the treated group was further markedly reduced (hazard ratio 0.17, 95% CI 0.04-0.68) compared with that in the control cohort.For ESRD patients with HCV infection, receiving interferon treatment is associated with a survival advantage. Such an advantage is more prominent in HCV patients without cirrhosis or hepatoma.
    Appears in Collections:[Dept. of Applied Life Science and Health] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    29684.pdf281KbAdobe PDF196View/Open
    index.html0KbHTML256View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback